Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA.
| Market Cap | 81.48 Million | Shares Outstanding | 29.522 Million | Avg 30-day Volume | 491.105 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.42 |
| Price to Revenue | 2.3285 | Debt to Equity | 0.3652 | EBITDA | -47.801 Million |
| Price to Book Value | 0.9192 | Operating Margin | -240.91429999999997 | Enterprise Value | 18.541 Million |
| Current Ratio | 4.855 | EPS Growth | 0 | Quick Ratio | 4.327 |
| 1 Yr BETA | 1.4177 | 52-week High/Low | 6.5 / 1.08 | Profit Margin | -251.0454 |
| Operating Cash Flow Growth | -57.9395 | Altman Z-Score | -1.8228 | Free Cash Flow to Firm | 0 |
| Earnings Report | 2023-05-09 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
NELSON TODD ROBERT PRESIDENT & CEO |
|
6,213,263 | 2022-11-11 | 1 |
|
GIBSON DANIEL GLENN CHIEF TECHNOLOGY OFFICER |
|
100,000 | 2022-08-04 | 1 |
|
HUNTER BRENT M. VICE PRESIDENT, FINANCE & PFO |
|
125,000 | 2022-08-04 | 2 |
|
ESSER ERIC EUGENE CHIEF OPERATING OFFICER |
|
50,000 | 2022-08-04 | 3 |
|
186,528 | 2022-07-20 | 2 | |
|
51,575 | 2022-06-09 | 1 | |
|
51,575 | 2022-06-09 | 1 | |
|
2,370,620 | 2022-06-09 | 1 | |
|
51,575 | 2022-06-09 | 1 | |
|
51,575 | 2022-06-09 | 2 | |
|
MCNEALEY JENNIFER ISACOFF CHIEF FINANCIAL OFFICER |
|
135,300 | 2022-02-27 | 0 |
|
0 | 2021-09-14 | 0 | |
|
0 | 2021-09-14 | 0 | |
|
RENAUD RONALD C JR CHIEF EXECUTIVE OFFICER |
|
0 | 2021-09-14 | 0 |
|
No longer subject to file | 2021-06-22 | 0 | |
|
No longer subject to file | 2021-06-22 | 0 | |
|
9,844,130 | 2021-06-22 | 0 | |
|
6,000,000 | 2021-06-22 | 0 | |
|
468,750 | 2021-06-22 | 0 | |
|
0 | 2021-06-17 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| TELESIS BIO INC TBIO | 2023-03-28 22:15:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 21:45:03 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 21:15:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 20:45:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 20:15:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 19:45:05 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 19:15:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 18:45:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 18:15:03 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 17:45:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 17:15:03 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 16:45:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 16:15:03 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 15:45:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 15:15:04 UTC | -19.8007 | 24.6207 | 25000 |
| TELESIS BIO INC TBIO | 2023-03-28 14:45:03 UTC | -19.8007 | 24.6207 | 20000 |
| TELESIS BIO INC TBIO | 2023-03-28 14:15:04 UTC | -19.8007 | 24.6207 | 20000 |
| TELESIS BIO INC TBIO | 2023-03-28 13:45:03 UTC | -17.3144 | 22.1344 | 20000 |
| TELESIS BIO INC TBIO | 2023-03-28 13:15:04 UTC | -17.3144 | 22.1344 | 20000 |
| TELESIS BIO INC TBIO | 2023-03-28 12:45:04 UTC | -17.3144 | 22.1344 | 30000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | TBIO | -900.0 shares, $-1125.0 | 2022-12-31 | N-PORT |
